Internal Medicine, Hematology & Oncology · Newport News, VA
NPI
1982718078
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1051 Loftis Blvd, Suite 100
Newport News, VA, 23606
Phone (757) 873-9400
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.4M
158,282 services
Medicare patients, 2024
795
Average age 75
Drug cost, 2024
$1.8M
698 prescriptions
Company payments, 2025
$65K
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David Z Chang was code J9263 (injection, oxaliplatin, 0.5 mg), 16,560 times for 11 patients. In total David Z Chang billed 158,282 services in 190 codes, and Medicare paid $2.4M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-09-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 16,560 | 11 | $0.05 | $908 |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 12,254 | 19 | $2.31 | $28K |
| J9025 Injection, azacitidine, 1 mg | Office | 12,100 | 15 | $0.29 | $3,538 |
| J1453 Injection, fosaprepitant, 1 mg | Office | 9,450 | 17 | $0.11 | $1,077 |
| J0185 Injection, aprepitant, 1 mg | Office | 4,940 | 14 | $1.37 | $6,780 |
| J0897 Injection, denosumab, 1 mg | Office | 3,600 | 30 | $18.34 | $66K |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2,710 | 20 | $35.63 | $97K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,701 | 88 | $0.09 | $241 |
| 85025 Blood Count | Office | 1,404 | 405 | $7.60 | $11K |
| 80053 Clinical Chemistry | Office | 1,272 | 375 | $10.32 | $13K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,160 | 31 | $0.70 | $808 |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 770 | 13 | $0.26 | $198 |
| 96375 Injection Administration | Office | 729 | 102 | $11.50 | $8,380 |
| J9190 Injection, fluorouracil, 500 mg | Office | 679 | 12 | $2.29 | $1,554 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 616 | 356 | $12.50 | $7,698 |
By year: 2022 $3.2M for 242,431 services; 2023 $2.6M for 157,142 services; 2024 $2.4M for 158,282 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,404 | 405 | $7.60 | $11K |
| 80053 Clinical Chemistry | 1,272 | 375 | $10.32 | $13K |
| 82784 Immunoassay | 366 | 64 | $9.05 | $3,311 |
| 83550 Clinical Chemistry | 264 | 128 | $8.51 | $2,247 |
| 82728 Clinical Chemistry | 264 | 128 | $13.27 | $3,503 |
| 83540 Clinical Chemistry | 263 | 128 | $6.30 | $1,656 |
| 83615 Clinical Chemistry | 228 | 129 | $5.90 | $1,344 |
| 81002 Clinical Chemistry | 138 | 15 | $3.41 | $471 |
| 82378 Clinical Chemistry | 130 | 65 | $18.58 | $2,415 |
| 36415 Venipuncture Blood Collection | 126 | 85 | $8.65 | $1,090 |
Medicare prescription drug claims, 2024
In 2024, the drug David Z Chang prescribed most often to Medicare patients was Xarelto (Rivaroxaban), with 52 prescriptions and refills. In total David Z Chang wrote 698 Medicare prescriptions that cost $1.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Xarelto Rivaroxaban | 52 | 68 | 13 | $36K |
| Letrozole Generic | 50 | 136 | 17 | $1,717 |
| Acyclovir Generic | 41 | 41 | Under 11 | $305 |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 38 | 38 | 27 | $472 |
| Dexamethasone Generic | 38 | 38 | 11 | $615 |
| Promethazine Hcl Generic | 32 | 32 | 22 | $151 |
| Ondansetron Hcl Generic | 28 | 28 | 18 | $882 |
| Revlimid Lenalidomide | 27 | 27 | Under 11 | $516K |
| Eliquis Apixaban | 23 | 27 | Under 11 | $15K |
| Ondansetron Odt Ondansetron | 21 | 21 | 16 | $524 |
| Fruzaqla Fruquintinib | 17 | 17 | Under 11 | $396K |
| Pazopanib Hcl Generic | 16 | 16 | Under 11 | $136K |
| Sodium Chloride 0.9 % Sodium Chloride | 15 | 15 | Under 11 | $690 |
| Enoxaparin Sodium Generic | 14 | 14 | Under 11 | $7,512 |
| Imatinib Mesylate Generic | 14 | 14 | Under 11 | $7,035 |
Brand drugs: 192 claims; generic drugs: 506 claims; opioid claims: 38.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David Z Chang $65K ($65K in general payments such as food, travel and fees) from 9 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $48K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.